Chemotherapy plus Ofatumumab at Standard or Mega dose In Chronic lymphoid leukemia (CLL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Bendamustine; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms COSMIC

Most Recent Events

15 Dec 2021 Status changed from active, no longer recruiting to completed.
25 Jun 2017 Primary endpoint (Proportion of patients achieving a Complete Response) has not been met, according to the abstract presented at the 22nd Congress of the European Haematology Association.
25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight